

Treatment Naïve and Treatment Experienced

Sofosbuvir + Peginterferon + Ribavirin in Genotypes 2 or 3 BOSON Trial

Foster GR, et al. 50th EASL. 2015. Abstract L05

Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3


BOSON Trial: Study Features

BOSON Trial: Features

- **Design:** Randomized, multicenter, open-label trial using sofosbuvir and ribavirin with or without peginterferon for treatment naive or experienced patients with chronic HCV genotype 2 or 3
- **Setting:** International at 80 sites
- **Entry Criteria**
 - Chronic HCV Genotype 2, treatment experienced, with cirrhosis
 - Chronic HCV Genotype 3, +/- treatment experienced, +/- cirrhosis
 - Platelet $\geq 60,000$ cells/mm³
- **End-Points:** SVR12; safety

Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

BOSON: Treatment Arms



Drug Dosing

Sofosbuvir 400 mg once daily


Ribavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg

Peginterferon alfa-2a: 180 ug/week

Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

BOSON: Results


SVR12 by Regimen and Genotype



Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

BOSON: Results


Genotype 3: SVR12 by Regimen



Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

BOSON: Results


Genotype 3: SVR12 by Regimen and Cirrhosis Status



Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

BOSON: Results

Genotype 3: SVR12 by Regimen and Treatment History



This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.